Risks

GLP-1 demand remains highly competitive versus Eli Lilly, but Novo Nordisk’s entrenched obesity and diabetes franchise still supports resilient volume and pricing.

Payer scrutiny on obesity-drug affordability can slow net price realization versus peers, yet Novo’s scale and formulary access help cushion reimbursement pressure.

Supply normalization risk persists after rapid category expansion, but Novo’s manufacturing footprint is better positioned than smaller peers to absorb demand swings.

Patent and lifecycle pressure on semaglutide will intensify over 1–5 years, although the company’s broader diabetes base reduces dependence versus single-product peers.

Opportunities

Obesity treatment adoption is still early, and Novo Nordisk’s leadership in GLP-1s positions it to capture incremental demand ahead of most diabetes-focused peers.

International expansion in obesity and diabetes remains underpenetrated, giving Novo a larger addressable market runway than U.S.-centric competitors.

Pipeline breadth beyond semaglutide, including next-generation incretins, supports share retention versus peers facing narrower follow-on innovation.

Strong cash generation and low leverage versus peers provide flexibility to fund capacity, launches, and market access initiatives without stressing the balance sheet.

Overall Score

Novo Nordisk combines exceptional obesity and diabetes demand exposure with strong financial flexibility, while competitive, pricing, and lifecycle risks remain manageable versus peers.